Rigel Pharmaceuticals (RIGL)
(Real Time Quote from BATS)
$13.87 USD
+0.24 (1.76%)
Updated Sep 19, 2024 02:56 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RIGL 13.87 +0.24(1.76%)
Will RIGL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RIGL
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for RIGL
Rigel to Present at the 2024 Cantor Global Healthcare Conference
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA? (olutasidenib) in mIDH1 AML
Rigel Pharmaceuticals: First patient enrolled in Phase 1b/2 REZLIDHIA trial
Buy Rating Affirmed for Rigel with Positive Outlook on Asian Market Expansion and Solid NPV Valuation
Rigel Expands Relationship with Kissei to include REZLIDHIA? (olutasidenib) in Japan, the Republic of Korea and Taiwan